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Objective: Our aim was to explore the effect of chondroitin sulfate (CS), a natural glycosaminoglycan with
attributed anti-inﬂammatory properties, on synovitis in a rabbit model of chronic arthritis with intense
systemic inﬂammation bolstered by endothelial lesion and atherosclerotic diet.
Methods: Chronic arthritis was induced by intraarticular injections of ovalbumin in immunized rabbits.
Systemic inﬂammation was boosted in these rabbits by receiving a hyperlipidemic diet after producing an
endothelial lesion in the femoral arteries. A group of these rabbits were treated with CS (100 mg/kg/day).
At sacriﬁce, synovial membranes were isolated, and cyclooxygenase-2 (COX-2) and chemokine (C-C motif)
ligand 2 (CCL2) mRNA, as well as protein expression were assayed by quantitative real-time polymerase
chain reaction (RT-PCR) and western blot studies. Histological synovial examination was also carried out
employing the histopathological synovitis score (Krenn scale).
Results: CS diminished both gene expression and protein synthesis of COX-2 and CCL2, and the histo-
pathological score of the synovial membrane, when compared to untreated rabbits. In fact, CS partially
prevented the intimal layer proliferation and the inﬂammatory cell inﬁltration in the synovial
membrane, which was observed in non-treated animals.
Conclusion: CS reduced the inﬂammatory response of the synovial membrane, as well as decreased the
synovial histopathological lesions in our animal model. Further studies are warranted to demonstrate
whether CS might be beneﬁcial in the treatment of inﬂammatory arthritis.
 2010 Osteoarthritis Research Society International. Published by Elsevier Ltd. All rights reserved.Introduction
Rheumatoid arthritis (RA) is a chronic systemic disease that
primarily affects the joints, and is characterized by prominent
inﬂammatory changes in the synovial membranes and articular
structures1. A characteristic activation of macrophages, B and T
lymphocytes, and endothelial cells plays a leading role in the
etiopathogenesis of the disease. Subsequently, the rheumatoid
membrane produces large amounts of proinﬂammatory cytokines
that leak into the blood increasing their serum concentrations
several fold and reaching other tissues. Moreover, the progression
of RA is driven by proinﬂammatory cytokines, chemokines, and
adipokines, as well as different T cell-dependent mediators2e5. In
particular, the chemokine (C-C motif) ligand 2 (CCL2) drives the
migration of mononuclear cells into the arthritic joint5,6, and the: Raquel Largo and Gabriel
ory, Fundación Jimenez Diaz,
04978; Fax: 34-915442636.
s Research Society International. Pcyclooxygenase-2 (COX-2) is a key enzyme in articular inﬂamma-
tion7. Remarkably, many of these relevant pathogenic mechanisms
that occur in chronic arthritis have also been associated with the
appearance of atherosclerotic plaque-related complications2,6,8,9.
The coexistence of these two conditions in our combined animal
model boosts an intense systemic inﬂammatory status which in
turn aggravates synovial inﬂammation10.
Chondroitin sulfate (CS) is a natural glycosaminoglycan (GAG)
that is predominantly found in the extracellular matrix, especially
in cells surrounding the cartilage, skin, blood vessels, ligaments and
tendons11,12. The administration of exogenous CS has been shown
to possess anti-inﬂammatory activity in chondrocytes and synovial
cells of patients with knee osteoarthritis (OA)13,14. Indeed, CS
reduces nitric oxide (NO) release, the activation of nuclear factor-kB
(NF-kB), and the synthesis of different proinﬂammatory mediators
involved in OA pathogenesis12,15e17. Moreover, CS has also been
demonstrated to decrease synovial inﬂammation and cartilage
damage in two animal arthritis models18,19.
The objective of this study was to examine the anti-inﬂamma-
tory properties of CS on the synovial changes and on markers ofublished by Elsevier Ltd. All rights reserved.
R. Largo et al. / Osteoarthritis and Cartilage 18 (2010) S17eS23S18inﬂammation in a rabbit model of chronic arthritis with intense
systemic inﬂammation boosted by endothelial lesion and hyper-
lipidemic atherosclerotic diet.Materials and methods
Experimental model of induced atherosclerosis in rabbits with
chronic arthritis
Thirty white adult New Zealand male rabbits (3.02 0.04 kg;
Granja San Bernardo, Navarra, Spain) were used in this study. All
animal handling and experiments were in accordance with Spanish
regulation and the Guidelines for the Care and Use of Laboratory
Animals drawn up by the National Institutes of Health. The protocol
(Fig. 1) was approved by the Institutional Ethics Committee.
A detailed description of the experimental animal model has
recently been published10,20. Brieﬂy, all rabbits were adapted to the
facilities for 2 weeks, and then separated into three groups of 10
animals each: a ﬁrst group of healthy rabbits fedwith standard chow
(control); a second group of rabbits with chronic antigen-induced
arthritis (AIA) and atherosclerosis (AIA-AT); and a third group of
rabbits with AIA-AT that received 100 mg/kg/day CS (AIA-ATþ CS).
All rabbits received either intraperitoneal injections of powdered CS
(Bioibérica SA, Barcelona, Spain) dissolved in 0.9%NaCl or the vehicle
alone over 5weeks. CS usedwas highly puriﬁed chondroitins 4 and 6
sulfate of bovine origin in a concentration not less than 98%. It has an
average molecular weight of w15e16 kDa and a 4-sulfated/6-
sulfated ratio of 2.0 (4s/6s ratio; the ratio between the sulfated
groups located in positions 4 and 6 on N-acetyl-D-galactosamine). CS
was dissolved once daily at a concentration of 400 mg/ml in sterile
0.9% NaCl, and every rabbit received the corresponding dose in
relation to its weight in each moment. To induce atherosclerosis, the
rabbits were fed with a hypercholesterolemic diet of 2% cholesterol
and 6% peanut oil (Letica, Barcelona, Spain) throughout the study.
Two weeks after starting the diet, an endothelial lesion was induced
in both femoral arteries by the intravascular instillation of nitrogen
gas under general anesthesia. To induce AIA, animals were given two
intradermal injections of 4 mg ovalbumin (OVA) in Freund’s
complete adjuvant, 14 days apart, beginning the same week as the
hyperlipidemic diet. Five days after the second injection, 1 ml OVA
(5 mg/ml in 0.9% NaCl) was intra-articularly injected into both knee
joints on aweekly basis over the following 4weeks. At the end of this
period, the animals were sacriﬁced and synovial membranes from
both knees were removed and divided for histological andmolecularChronogram of the antigen-induced arthritis model
Immunization
SacrificeEndothelial surgery 
Chronogram of the atherosclerosis model
Hypercholesterolemic diet
Intra-articular OVA injections
weeks
CS administration (100 mg /kg /day)
Fig. 1. Schematic representation of the experimental model. The upper part of the
graphic shows a chronogram of the AIA model, while the lower part shows the
chronogram for the atherosclerosis (AT) model induction. Modiﬁed from Herrero-
Beaumont et al.17.biology studies. None of the animals, treated or untreated with CS,
died during the study. However, due to the lost of some samples
during the different procedures, the ﬁnal number of rabbits for each
experiment ranged between 8 and 10.
Histopathological analysis of the synovial lesions
Parafﬁn-embedded knee synovial sections were prepared and
stainedwith hematoxylineeosin andMasson’s trichrome. Synovitis
was evaluated in each sample according to the Krenn scale21 by two
observers in a blinded fashion, as described previously22,23.
Immunohistochemistry
We identiﬁed macrophages in the synovial sections using
a monoclonal anti-rabbit macrophage antibody (RAM11; Dako,
Glostrup, Denmark), according to a protocol previously described10.
The antibody was detected with a biotinylated goat anti-mouse IgG
visualized with a horseradish peroxidase/ABComplex using 3,3-
diaminobenzidine tetra-hydrochloride as the chromagen (Dako).
The tissues were counterstained with hematoxylin and mounted in
Pertex (Medite, Burgdorf, Germany). Computer-assisted analysis
was performed with the Olympus semiautomatic image analysis
system with Image-Pro Plus software (version 4.5 for
Windows)10,23. Results were expressed as percentage of positive
staining. An IgG isotype was used as a negative control.
RNA extraction and real-time polymerase chain reaction (RT-PCR)
Synovial tissue was homogenized in liquid nitrogen, and total
RNA was extracted from the resulting powder using Trizol reagent
(Roche, Mannheim, Germany) according to the manufacturer’s
instructions. First-strand cDNA was synthesized from 1 mg of total
RNA using the High-Capacity cDNA Reverse Transcription Kit
following the manufacturer’s guidelines (Applied Biosystems,
Stockholm, Sweden). PCR primers and probes were designed by
Applied Biosystems, and the endogenous control in these assays
was the eukaryotic 18S rRNA. Ampliﬁcation reactions and ﬂores-
cence detection were performed in an ABI Prism 7500 Sequence
Detection System. Thermal cycling was carried out for 10 min at
95C, followed by 40 cycles of 15 s at 95C and 1 min at 60C.
Relative quantiﬁcation was performed with the ABI Prism 7500
System SDS software (Applied Biosystems) and the results are
expressed in terms of the n-fold increase in expression with regard
to a reference sample, using the DDCt method from the average Ct
value of the target gene.
Western blot analysis
Synovial tissue was homogenized in liquid nitrogen, and total
proteinwasextracted fromthe resultingpowderby theTrizolmethod
(Roche, Mannheim, Germany). Once precipitated in ethanol, the
proteins were solubilized in 1% sodium dodecyl sulfate (SDS) and
resolved on10% acrylamide-SDS gels. After transfer to polyvinylidene
diﬂuoride (PVDF) membranes, the lysates were probed with anti-
bodies against COX-2 (Santa Cruz Biotech, Heldelberg, Germany) and
a-tubulin (Sigma Chemicals, St Louis, MO, USA), as previously
described10. Brieﬂy, the PVDF membranes were blocked in 5% skim-
med milk in PBS-Tween 20 for 1 h at room temperature and then
incubated overnight at 4C with the primary antibodies. Antibody
binding was detected by enhanced chemoluminiscence using
peroxidase-conjugated secondary antibodies, and the results were
expressed as arbitrary densitometric units normalized to the a-
tubulin levels.
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The data are expressed as the means SE, and they were
analyzed using the ManneWhitney U-test. Where multiple
comparisons were performed, the KruskaleWallis test was used.
Statistical signiﬁcance was set at P< 0.05. All statistical analyses
were performed using Windows SPSS version 11.0 software (SPSS,
Chicago, IL, USA).Results
Histopathological analysis of the synovial membrane
Figure 2 shows representative photomicrographs of synovial
tissues from rabbits in each group. AIA-AT rabbits displayed
widespread lesions involving intimal hyperplasia andmononuclear
cell inﬁltration at the subintima, lesions that were frequently
associated with aggregate formation [Fig. 2(B)]. In these animals,
the characteristic adipose-rich interstitium of the healthy syno-
vium [Fig. 2(A)] was replaced by recruited cells and by areas of
ﬁbrosis [Fig. 2(B, C)]. In AIA-ATþ CS rabbits, synovial lesions were
not so severe [Fig. 2(D, E)]. Indeed, the intimal hyperplasiawas focal
[Fig. 2(D)], and mononuclear cell inﬁltrates were smaller. Accord-
ingly, the semiquantitative synovitis score showed signiﬁcant
differences between both groups [P¼ 0.003; Fig. 2(F)].Immunohistochemical staining of synovial macrophages
Figure 3 shows representative immunohistochemical sections
from synovial tissues where RAM11 positive cells were stained.
While no positive staining was observed for control animals (data
not shown), AIA-AT rabbits show an intense staining both in the
intimal layer and in the synovial stroma [Fig. 3(AeC)]. In AIA-
ATþ CS rabbits, RAM11 staining was observed in the same locali-
zations than that observed for AIA-AT rabbits [Fig. 3(DeF)].
However, quantiﬁcation of tissue staining revealed a signiﬁcant
decrease in the percentage of stained area in the synovial
membrane of AIA-ATþ CS rabbits in comparison to AIA-AT animals
[Fig. 3(G)].Fig. 2. Histopathology of the synovial membrane. AeE: hematoxylineeosin stained sections
rabbits. Original magniﬁcation 100 for all the photographs; F: densitometric analysis of
*P< 0.05 vs control; #P< 0.05 vs AIA-AT rabbits. N¼ 8e10 animals per group.COX-2 expression in the synovial membrane
Both COX-2 gene and protein expression in the synovial
membrane were signiﬁcantly increased in AIA-AT animals when
compared with the control rabbits (P¼ 0.011 and P¼ 0.001,
respectively). The administration of CS signiﬁcantly diminished
both COX-2 gene and protein expression in synovial tissue
(P¼ 0.042 and P¼ 0.012, respectively) [Fig. 4(A, B)].CCL2 expression in the synovial membrane
The induction of the combined disease model (AIA-AT rabbits)
leads to a signiﬁcant increase in CCL2 gene expression when
compared with healthy rabbits (P¼ 0.009; Fig. 5), while the
expression of the CCL2 gene in these animals was down-regulated
by CS administration (3.0 0.6 vs 10.2 0.9; P¼ 0.001). It is note-
worthy that CCL2 gene expression in the synovial membrane was
positively correlated to the percentage of synovial macrophage
staining in this tissue (r¼ 0.870; P< 0.001).Discussion
We have studied the CS effects on the synovial inﬂammatory
changes that occur in chronic AIA rabbits10. AIA is awell established
experimental arthritis model which presents two phases. The ﬁrst
phase, an acute stage whereby Th1 cell function plays an essential
pathogenic role and joint swelling and a pluricellular inﬁltrate is
observed. The second phase, a subsequent chronic stage, charac-
terized by pannus formation and matrix degradation24,25.
Remarkably, we have modiﬁed the arthritis induction by increasing
the number of intraarticular injections, as a consequence, our
animal model develops a more aggressive synovitis10. The AIA
rabbit model has been described as insensitive to NSAIDs26,
although shows good response to steroids, gold compounds, and
particularly to cytotoxic drugs25,27.
In our experimental model, rabbits with chronic AIA-AT display
widespread and severe synovial lesions10. They include marked
intimal hyperplasia and intense mononuclear cell inﬁltration at the
subintima that are frequently associated with aggregate formation,of synovial membranes from control (A), AIA-AT (B and C) and AIA-ATþ CS (D and E)
the global synovitis score in the three study groups. The bars show the mean S.E.M.
Fig. 3. Photographs of representative monoclonal anti-rabbit macrophage antibody (RAM11) stained sections in the synovial membrane from AIA-AT (AeC) and AIA-ATþ CS (D, E)
rabbits. Original magniﬁcation: 100 for all of them. G: densitometric analysis of RAM11 staining in the synovial membrane of each group of animals. Bars represent the
mean S.E.M. *P< 0.05 vs control; #P< 0.05 vs AIA-AT rabbits. N¼ 8e10 animals per group.
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matoid synovitis10,28. Thus, AIA-AT rabbit represents an useful
experimental model to test anti-rheumatic drugs, due to its simi-
larity to human RA29.
In the present study CS signiﬁcantly decreased the histopatho-
logical parameter of synovitis such as the semiquantitative Krenn
score, the mononuclear cell inﬁltrate and the intimal hyperplasia
observed in AIA-AT rabbits. These CS beneﬁcial effects are in
agreement with those from previous in vivo studies carried out in
other arthritis animal models. In fact, CS signiﬁcantly diminished
cell inﬁltration, ﬁbrosis and proliferation of synovial lining cells in
the murine collagen-induced arthritis (CIA) model18. Also, CS
inhibited the production of edema, and prevented both cartilage
damage and increase of the levels of joint metalloproteinase-9
(MMP-9) in the rat Freund’s adjuvant-induced arthritis19. In addi-
tion, the association of CS plus GS reduced signiﬁcantly clinical and
histological parameters of inﬂammation in the last animal model19.
CS decreased the number of inﬁltrated macrophages in syno-
vium of the AIA-AT rabbit model in the current study. Synovial
macrophages play a central role in the development of AIA and the
pathogenesis of RA, and the inﬁltration of the synovium with
sensitized macrophages may have increased the severity of the
local inﬂammatory response in these animals. Furthermore, CS
decreased the gene expression of CCL2, a chemokine that mediates
the migration of mononuclear cells to the inﬂamed joint and itsinduction could explain the persistent activation of these cells that
are involved in joint destruction21,22. Remarkably, a very good
correlation existed between CCL2 gene expression and the
percentage of stained synovial macrophages, thus, supporting the
relevant role of CCL2 in the formation of inﬂammatory cellular
inﬁltrates in the arthritic synovium. CS has been also shown to
reduce the levels of circulating and synovial inﬂammatory cyto-
kines associated with a great immunologic activation and potential
for joint destruction in RA patients30e32. In this fact, CS treatment
signiﬁcantly reduced interleukin IL-1b (IL-1b) levels in joint tissues
in adjuvant-induced arthritis19. Moreover a signiﬁcant decrease in
the TNF-a and IL-6 levels, and myeloperoxidase activity in the
plasma was found in CIA rats following CS treatment33. Similarly,
intraperitoneal CS administration diminished malonaldehyde
levels (an indicator of lipid peroxidation) and reversed the deple-
tion of the endogenous antioxidants reduced glutathione and
superoxide dismutase, both relevant mechanisms of cartilage
damage in the rat Freund’s adjuvant arthritis model19.
Finally, the expression of the inducible COX-2 enzyme, which
plays a key role in arthritis-associated inﬂammation and pain, was
signiﬁcantly decreased by CS administration to rabbits with chronic
AIA-AT. Similar results have been obtained in in vitro studies carried
out with bovine articular cartilage explants, whereby CS treatment
suppressed IL-1b-induced inducible NO synthase, COX-2 and
prostaglandin E (PGE)-2 gene expression34. Moreover, similar data
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Fig. 4. COX-2 mRNA and protein expression in the synovial membrane. A top: repre-
sentative western blot of COX-2 protein expression in the synovial membrane. A
bottom: densitometric analysis of COX-2 protein expression in the synovial membrane,
assessed by western-blots. B: COX-2 mRNA expression measured by real-time PCR in
the synovial membrane. Bars represent the mean S.E.M. *P< 0.05 vs control; #P< 0.05
vs AIA-AT rabbits. N¼ 8e10 animals per group.
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recent study reported that CS reduces IL-1b-induced phosphory-
lation of the extracellular signal-regulated kinase 1/2 and p38
mitogen-activated protein kinase and the nuclear transactivation ofCONTROL AIA-AT AIA-AT+CS
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Fig. 5. Densitometric analysis of CCL2 mRNA expression in the synovial membrane
measured by real-time PCR. Bars represent the mean S.E.M. *P< 0.05 vs control;
#P< 0.05 vs AIA-AT rabbits. N¼ 8e10 animals per group.NF-kB in chondrocytes36. The reduction in the expression and/or
activity of these inﬂammatory molecules may explain the mecha-
nisms by which CS potentially exerts its beneﬁcial effect not only in
the synovium but also on the articular cartilage and subchondral
bone during arthritis.
Our study has some obvious major limitations. The inﬂamma-
tion in our animalmodel is not entirely originated from the arthritic
process but from the association between this process and the
presence of atherosclerosis and endothelial lesion10. Nonetheless,
CS has showed a clear negative effect on such marked synovial
inﬂammatory status. Additionally, CS is administered orally to
patients, and in this study it was administered intraperitoneally.
The doses of CS given to the rabbits were around 10 times higher
than those used in humans to treat OA37. However, due to the slow
onset of action of this drug, and to the different bioavailability and
doseeresponse curves between species, similar doses have been
employed in experimental models of tissue injury when addressing
this hypothesis15,38. Finally, CS was employed as a prophylactic
agent, to detect a potential therapeutic effect as usual in this type of
studies. Once this effect has been demonstrated, it must be
conﬁrmed in a designed therapeutic study. However, the present
results are relevant as they can be potentially used to design studies
to test the effects of CS in chronic arthritis.
In summary, our results show that CS exerts a clear anti-
inﬂammatory effect on synovitis in our rabbit model of AIA with
associated severe systemic inﬂammation elicited by endothelial
lesion and atherosclerosis. Further studies are warranted to
demonstrate whether CS might be beneﬁcial in the treatment of IA.
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